Limosilactobacillus fermentum KBL674 Alleviates Vaginal Candidiasis
Probiotics and Antimicrobial Proteins · 2025
DOI: 10.1007/s12602-024-10403-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Probiotics and Antimicrobial Proteins, 2025. Verfasst von Sung Jae Jang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Environmental Health Sciences, Graduate School of Public Health, Seoul National University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Candidiasis, Vulvovaginal, Limosilactobacillus fermentum, Candida albicans, Probiotics. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seoul National University.
Abstract (Originalsprache)
Candida albicans ( C. albicans ) is the primary etiologic agent of vaginal candidiasis. Lactobacillus species are predominant in the vaginal microbiome; they inhibit the development of vaginal candidiasis by producing antimicrobial agents, such as lactic acid and hydrogen peroxide. In this study, we investigated the effects of Limosilactobacillus fermentum ( L. fermentum ) KBL674 in a mouse model of vaginal candidiasis. L. fermentum KBL674 inhibited C. albicans hyphal growth. Moreover, oral administration of L. fermentum KBL674 significantly suppressed vaginal C. albicans infection and associated symptoms, including tissue thickness and immune cell infiltration. A substantial quantity of L. fermentum KBL674 was excreted by the mice within 6 h after oral administration, indicating that most L. fermentum KBL674 did not settle within the gastrointestinal tract. L. fermentum KBL674 modulated gut microbiome diversity, increasing abundances of the genera Akkermansia , Eubacterium , and Faecalibaculum and family Muribaculaceae . Abundances of these bacteria showed negative correlations with the vaginal C. albicans burden in the mouse model, suggesting links between the gut microbiome composition and the vaginal C. albicans burden . Therefore, L. fermentum KBL674 can reduce the vaginal C. albicans burden via direct or indirect inhibition and modulation of the gut microbiome composition preventively. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Environmental Health Sciences, Graduate School of Public Health, Seoul National University, Seoul, Republic of Korea.
- weBiom Inc., Seoul, Republic of Korea.
- KoBioLabs, Inc, Seoul, Republic of Korea.
- Institute of Health and Environment, Seoul National University, Seoul, Republic of Korea.
- The Food Industry Promotional Agency of Korea, Iksan-Si, Jeollabuk-Do, Republic of Korea.
- weBiom Inc., Seoul, Republic of Korea. haha7007@snu.ac.kr.
Förderung
- Seoul National University
Zitieren
APA
Jang, S. J., Jo, E. J., Lee, C., Cho, B. R., Shin, Y. J., Song, J. S., Kim, W. K., Lee, N., Lee, H., Park, S., & Ko, G. (2025). Limosilactobacillus fermentum KBL674 Alleviates Vaginal Candidiasis. Probiotics and Antimicrobial Proteins. https://doi.org/10.1007/s12602-024-10403-3
Vancouver
Jang SJ, Jo EJ, Lee C, Cho BR, Shin YJ, Song JS, et al. Limosilactobacillus fermentum KBL674 Alleviates Vaginal Candidiasis. Probiotics and Antimicrobial Proteins. 2025. doi:10.1007/s12602-024-10403-3
BibTeX
@article{Jang2025,
author = {Jang, Sung Jae and Jo, Eun Jung and Lee, Cheonghoon and Cho, Bo-Ram and Shin, Yun Jeong and Song, Jun Soo and Kim, Woon-Ki and Lee, Nanhee and Lee, Hyungjin and Park, SungJun and Ko, GwangPyo},
title = {Limosilactobacillus fermentum KBL674 Alleviates Vaginal Candidiasis},
journal = {Probiotics and Antimicrobial Proteins},
year = {2025},
doi = {10.1007/s12602-024-10403-3}
}
EUVIMED